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Summary
Background Medication errors are common in primary care and are associated with considerable risk of patient harm. 
We tested whether a pharmacist-led, information technology-based intervention was more eﬀ ective than simple 
feedback in reducing the number of patients at risk of measures related to hazardous prescribing and inadequate 
blood-test monitoring of medicines 6 months after the intervention. 
Methods In this pragmatic, cluster randomised trial general practices in the UK were stratiﬁ ed by research site and list 
size, and randomly assigned by a web-based random isation service in block sizes of two or four to one of two groups. The 
practices were allocated to either computer-generated simple feedback for at-risk patients (control) or a pharmacist-led 
information technology intervention (PINCER), composed of feedback, educational outreach, and dedicated support. 
The allocation was masked to researchers and statisticians involved in processing and analysing the data. The allocation 
was not masked to general practices, pharmacists, patients, or researchers who visited practices to extract data. Primary 
outcomes were the proportions of patients at 6 months after the intervention who had had any of three clinically 
important errors: non-selective non-steroidal anti-inﬂ ammatory drugs (NSAIDs) prescribed to those with a history of 
peptic ulcer without co-prescription of a proton-pump inhibitor; β blockers prescribed to those with a history of asthma; 
long-term prescription of angiotensin converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older 
without assessment of urea and electrolytes in the preceding 15 months. The cost per error avoided was estimated by 
incremental cost-eﬀ ectiveness analysis. This study is registered with Controlled-Trials.com, number ISRCTN21785299.
Findings 72 general practices with a combined list size of 480 942 patients were randomised. At 6 months’ follow-up, 
patients in the PINCER group were signiﬁ cantly less likely to have been prescribed a non-selective NSAID if they had 
a history of peptic ulcer without gastroprotection (OR 0∙58, 95% CI 0∙38–0∙89); a β blocker if they had asthma (0∙73, 
0∙58–0∙91); or an ACE inhibitor or loop diuretic without appropriate monitoring (0∙51, 0∙34–0∙78). PINCER has a 
95% probability of being cost eﬀ ective if the decision-maker’s ceiling willingness to pay reaches £75 per error avoided 
at 6 months.
Interpretation The PINCER intervention is an eﬀ ective method for reducing a range of medication errors in general 
practices with computerised clinical records.
Funding Patient Safety Research Portfolio, Department of Health, England.
Introduction
Medication errors are an important cause of potentially 
avoidable morbidity and mortality in primary1,2 and 
secondary care3 and reports from the USA, the UK, and 
elsewhere have shown the urgent need to reduce the risk 
of occurrence of these errors.4–6 Although important 
progress has been made in the implementation of 
interventions for use in specialist care settings,7 parti-
cularly in relation to computerised entry of physician 
orders7,8 and computerised decision support,9 the evidence 
for primary care—in which most patients are now 
managed worldwide—is still very weak.8,10
On the basis of systematic reviews of published work10,11 
and our own research,12,13 we identiﬁ ed the drugs most 
commonly associated with medication errors in primary 
care.11–13 In view of the few known eﬀ ective interventions, 
we focused on the identiﬁ cation of the most promising 
components of any future intervention.10 The evidence 
was strongest for educational outreach14 and pharmacist-
led interventions.10 Furthermore, most preventable 
adverse drug events in primary care are attributable to 
errors in prescription and medication monitoring,2,12 and 
changes in practice enabled by information technology 
have substantial potential to reduce the frequency of 
these errors.8 However, translation of this potential into 
proven beneﬁ ts is far from straightforward, which relates 
to the diﬃ  culties in making the organisational changes 
needed to embed information technology into routine 
models of care.15 The need for a new multifaceted 
intervention has been further underscored by two trials 
that have raised serious doubts about the eﬀ ectiveness of 
simple pharmacist-centred interventions.16,17
Informed by the Medical Research Council’s frame-
work for complex interventions,18 we aimed to test 
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whether an information technology intervention for 
pharmacists could improve prescription safety and 
medication monitoring in general practices. We also 
undertook an indicative analysis of the cost-eﬀ ectiveness 
of the intervention.
Methods
Study design and participants
We did a two-group pragmatic cluster randomised trial. 
Further details of the methods are available in the trial 
protocol.19 We chose a cluster design because the 
intervention was applied by the general practice. General 
practices were eligible to participate if they were 
computerised with electronic prescribing. Practices were 
excluded if they did not routinely record morbidities such 
as asthma or peptic ulcer in patients’ computerised 
records; did not routinely use computers to record 
prescriptions issued; intended to change their computer 
systems during the study to that of a diﬀ erent supplier 
that was not compatible with Quest Browser; were in 
primary care trusts that were undertaking interventions 
that might overlap with our intervention; took part in the 
pilot study of the trial; or expected large changes in list-
size (numbers of registered patients) during the study.
The study was approved by the Nottingham 2 research 
ethics committee. We obtained written consent from all 
general practices after a face-to-face meeting at which the 
study was explained in more detail. For the economic 
analysis, the general practices recruited to the study were 
asked to write to all patients identiﬁ ed through baseline 
data collection who appeared in the numerator of one of 
our outcome measures (ie, they had a potential medi-
cation error). Patients were given a leaﬂ et about the study 
and were asked to give written consent for the research 
team to access their medical records.
Randomisation and masking
We stratiﬁ ed eligible practices by centre (Manchester and 
Nottingham) and list size (<2500, 2500–6000, and 
>6000 patients) and randomly allocated them within 
strata (1:1 ratio) to receive the intervention or control by 
block randomisation with block sizes of two or four. The 
allocation sequence was centrally generated, independent 
of the investigators, by the clinical trials unit at the 
University of Nottingham (UK). Practices were enrolled 
by the research team and allocated by the independent 
web-based randomisation service provided by the unit. 
Access to the allocation sequence was restricted to the 
clinical trials unit data manager and the sequence was 
concealed until all analyses were completed.
General practices, patients, pharmacists, and research-
ers visiting practices to extract computerised data were 
not masked to the allocation. All outcome data for the 
trial were extracted from patient records by prespeciﬁ ed 
electronic searches and so these data could not be altered 
before leaving the practice. Data were then sent 
electronically by secure ﬁ le transfer protocol and 
automatically entered into a database on the trial 
manager’s computer. Researchers who cleaned the data 
and the trial statisticians were masked to allocation.
Procedures
Because patients were proactively identiﬁ ed as being at 
high risk of potentially serious errors, we judged that a 
control group of no intervention was unethical. The 
control group practices therefore used simple feedback; 
Panel 1: Outcomes
Primary
1 Patients with a history of peptic ulcer who have 
been prescribed a non-selective non-steroidal 
anti-inﬂ ammatory drug without co-prescription of a 
proton-pump inhibitor
2 Patients with asthma who have been prescribed a β blocker
3 Patients aged 75 years and older who have been 
prescribed an angiotensin converting enzyme inhibitor or 
a loop diuretic long-term who have not had a 
computer-recorded check of their renal function and 
electrolytes in the previous 15 months
Secondary
2a Patients with asthma (and no history of coronary heart 
disease) who had been prescribed a β blocker
4 Proportions of women with a past medical history of 
venous or arterial thrombosis who had been prescribed 
the combined oral contraceptive pill
5 Patients receiving methotrexate for at least 3 months 
who had not had a full blood count recorded (5a), or liver 
function test (5b), in the previous 3 months
6 Patients receiving warfarin for at least 3 months who had 
not had a recorded check of their international normalised 
ratio in the previous 12 weeks
7 Patients receiving lithium for at least 3 months who had 
not had a recorded check of their lithium concentrations 
in the previous 3 months
8 Patients receiving amiodarone for at least 6 months who 
had not had a thyroid function test in the previous 
6 months
9 Patients receiving prescriptions of methotrexate without 
instructions that the drug should be taken every week
10 Patients receiving prescriptions of amiodarone for at least 
1 month who are receiving a dose of more than 200 mg 
per day
Composite secondary outcome measures
11 Patients with at least one prescription problem 
(a combination of outcome measures 1, 2, or 4)
12 Patients with at least one monitoring problem 
(a combination of outcome measures 3, 5, 6, 7, and 8)
In the trial protocol19 composite outcome measures for patients with two or more 
prescription or monitoring problems were suggested. However, the number of 
patients with two or more problems was very small and so these ﬁ ndings are not 
reported in this Article.
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after collection of data at baseline, control practices 
received computerised feedback for patients identiﬁ ed as 
at risk from potentially hazardous prescripting and 
inadequate blood-test monitoring of medicines plus brief 
written educational materials explaining the importance 
of each type of error. Practices were asked to introduce 
changes they considered necessary within 12 weeks after 
the collection of data at baseline.
Intervention practices received simple feedback plus a 
pharmacist-led information technology complex inter-
vention (PINCER) lasting 12 weeks. The pharmacist 
arranged to meet with members of the practice team to 
discuss the computer-generated feedback for patients with 
medication errors. All doctors were encouraged to attend 
this meeting with at least one member of the nursing 
staﬀ , the practice manager, and at least one member of the 
reception staﬀ . Before the meeting, whenever possible, all 
relevant members of staﬀ  were provided with a brief 
summary of the objectives of the PINCER intervention 
and a summary of the ﬁ ndings from the computer search. 
At the meeting the pharmacists were asked to use the 
principles of educational outreach while taking account of 
human error theory in their discussions. After this initial 
meeting, pharmacists were expected to use various 
techniques to help correct medication errors that had been 
identiﬁ ed and prevent future medication errors. Inter-
ventions included review of patients’ medical records; 
discussions with family doctors to decide on actions to be 
taken; invitation of patients to be reviewed or to have blood 
tests; and working with members of the practice team to 
improve local safety systems. Details are provided in the 
trial protocol.19 All general practices had access to some 
computerised decision support, such as drug interactions, 
for prescription.
Data were extracted at baseline and at 6 months and 
12 months after the intervention with Quest Browser 
software (version 2.3.39).
We chose our primary and secondary outcomes on the 
basis of medicines management diﬃ  culties that are 
important in overall burden and severity of iatrogenic 
harm in primary care,11–13 and those that are detectable 
from general practice computer systems. The three 
primary outcomes assessed after 6 months were 
(1) prescription of non-selective non-steroidal anti-
inﬂ ammatory drugs (NSAIDs) to patients with a history 
of peptic ulcer without co-prescription of a proton-pump 
inhibitor (PPI); (2) prescription of β blockers to patients 
with a history of asthma; and (3) long-term prescription 
of angiotensin converting enzyme (ACE) inhibitors or 
loop diuretics to patients 75 years or older without 
assessment of urea and electrolytes in the preceding 
15 months. Panel 1 shows the primary, secondary, and 
composite outcomes (see also the trial protocol19).
Statistical analysis
Characteristics of practices and participants were 
recorded at baseline and compared informally between 
treatment groups.19 The prevalences of primary and 
secondary outcomes were measured at each timepoint by 
allocation group, at the level of the patient, using the 
numerator, denominator and percentage.
Analysis was by intention to treat.20,21 All outcome 
measures were binary and were compared between 
groups by random eﬀ ects logistic regression, with 
patient at level one and practice at level two, to estimate 
odds ratios and 95% CIs. The primary analysis adjusted 
for stratum as a ﬁ xed eﬀ ect (practice level), errors 
related to medication at baseline (patient level), 
deprivation,22 and training status (practice level). 
We estimated intraclass correlation coeﬃ  cients from 
these models.
Subgroup analyses for primary outcome measures 
assessed whether the intervention eﬀ ect varied by practice 
size or practice deprivation by incorporation of a term for 
the interaction between treatment group and the 
(continuous) covariate of interest into regression 
models.23 We categorised the covariate at the median 
value when there was evidence of non-linearity.
Patient characteristics Simple feedback PINCER
Primary outcomes
1 History of peptic ulcer prescribed an NSAID without a PPI/
history of peptic ulcer without a PPI
93/1970 (5%) 87/1828 (5%)
2 Asthma prescribed a β blocker/asthma 628/20 634 (3%) 537/18 906 (3%)
3 Aged ≥75 years receiving long term ACE inhibitors or loop 
diuretics without urea and electrolyte monitoring in the 
previous 15 months/aged ≥75 years receiving long-term 
ACE inhibitors or diuretics
483/4722 (10%) 549/4349 (13%)
Secondary outcomes
2a Asthma and not CHD prescribed a β blocker/asthma and 
not CHD
375/19 528 (2%) 337/17 968 (2%)
4 History of venous or arterial thrombosis prescribed 
combined oral contraceptives/history of venous or arterial 
thrombosis (women)
16/2588 (1%) 5/2284 (<1%)
5a Methotrexate for ≥3 months without full blood count in 
past 3 months/methotrexate for ≥3 months
202/483 (42%) 170/480 (35%)
5b Methotrexate for ≥3 months without a liver function test in 
past 3 months/ methotrexate for ≥3 months
184/483 (38%) 172/480 (36%)
6 Warfarin for ≥3 months without an INR in past 3 months/
warfarin for ≥3 months
99/1496 (7%) 92/1591 (6%)
7 Lithium for ≥3 months without a lithium concentration 
measurement in past 3 months/lithium for ≥3 months
101/224 (45%) 97/194 (50%)
8 Amiodarone for ≥6 months without a thyroid function 
test in the past 6 months/amiodarone for ≥6 months
130/253 (51%) 111/240 (46%)
9 Methotrexate without instructions to take weekly/patients 
prescribed methotrexate
12/345 (3%) 7/305 (2%)
10 Amiodarone for ≥1 month at a dose of >200 mg per day/
amiodarone for ≥1 month
1/223 (<1%) 1/222 (<1%)
11 At least one prescription problem/at risk of at least one 
prescription problem
736/24 550 (3%) 629/22 473 (3%)
12 At least one monitoring problem/at risk of at least one 
monitoring problem
1015/6756 (15%) 1018/6371 (16%)
Data are numerator/denominator (%). NSAID=non-steroidal anti-inﬂ ammatory drug. PINCER=pharmacist-led 
information technology intervention. ACE=angiotensin converting enzyme. PPI=proton-pump inhibitor. 
CHD=coronary heart disease. INR=international normalised ratio.
Table 1: Characteristics of patients at baseline by allocation group according to outcome measure 
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Signiﬁ cance was assessed with likelihood ratio tests 
with a p value of less than 0∙05. All analyses were done 
with Stata (version 10.1).24 We obtained outcome data for 
all participating practices at both the 6 months (primary) 
and 12 months assessment points, no data were missing. 
No adjustments were made for multiple endpoints. We 
checked models by examining plots of standardised 
empirical Bayes estimates for the random eﬀ ects and did 
sensitivity analyses by excluding practices with estimates 
above or below two standard deviations.
We calculated sample sizes separately for all primary 
outcomes. To calculate sample sizes unadjusted for 
clustering we used nQuery Advisor (version 6.0),25 and to 
inﬂ ate to adjust for clustering26 we used intraclass 
correlation coeﬃ  cients and average cluster sizes 
estimated from 43 general practices that contributed 
anonymous clinical data to the QResearch database 
(webappendix).19 66 practices were needed to detect a 
diﬀ erence between an 11% reduction in error rate in the 
simple feedback group and a 50% reduction in the 
PINCER group for the primary outcome measures with 
80% power and a two-tailed α of 0∙05.
In a prospective economic evaluation (webappendix), 
we compared PINCER with simple feedback for reduction 
of proportions of patients at risk from prescription errors 
in general practice, from the perspective of the UK NHS. 
Costs and outcomes associated with sequelae of errors 
were not included.
The outcome for the economic analysis was the number 
of errors detected in the PINCER and simple feedback 
groups at 6 months and 12 months after the intervention. 
We used outcome measures 1, 2, 3, 5a, 5b, 7, and 8 (table 1). 
We excluded outcome measure 4 because the number of 
patients with errors was very small and outcome 
measures 6, 9, and 10 because obtaining full data in all 
practices was diﬃ  cult.19
Costs were the direct costs of provision of an 
intervention to reduce prescription errors in general 
practice. The study was not powered to detect diﬀ erences 
in costs because no previous study on which to base a 
power calculation exists. The time horizon was 6 months 
in the base case. Because all costs were incurred by the 
practices, correction for clustering was not needed.
The only cost for the simple feedback group was 
from the researchers returning to the practices at set 
times to generate error reports from general practice 
systems. This cost was retained in the model to account 
for the equivalent resource that would be used to gene-
rate these error reports in the real world. The PINCER 
intervention consisted of these report-generation costs, 
plus pharmacist training sessions, facilitated meetings, 
monthly meetings, practice feedback meetings, and 
time spent in each practice outside meetings following 
up errors.
Before incremental cost-eﬀ ectiveness analysis, we 
adjusted costs and outcomes for a range of practice 
characteristics. We used the negative binomial model27 
for regression analysis of errors because variance was 
greater than the mean for errors per practice in both 
groups (overdispersion), and the variation diﬀ ered 
between groups. Poisson regression would under-
estimate the standard errors of the coeﬃ  cients. We 
estimated adjusted costs by generalised linear modelling. 
A simple probabilistic decision-analytic model was 
populated to generate incremental cost-eﬀ ectiveness 
ratios, which were calculated for diﬀ er ences in error 
rates between the PINCER and simple feedback groups:
To identify the magnitude of uncertainty of the incre-
mental cost-eﬀ ectiveness ratios, we generated a bootstrap 
estimate of the incremental cost-eﬀ ectiveness ratio 
sampling distribution. We constructed a cost-eﬀ ectiveness 
Figure 1: Trial proﬁ le
*Repeated cross-sectional design accounts for no loss to follow-up of patients. PINCER=pharmacist-led 
information technology-based intervention.
3 excluded
1 with pharmacist employed
1 with student population
1 not laboratory-linked
240 practices invited to participate
76 agreed to face-to-face consent
visit meeting
72 randomised (480 942 patients)
36 allocated to receive
simple feedback 
32 938 patients at risk
at baseline
(for all outcomes)
9 patients excluded from
outcome 3 analysis because
of data quality problems
36 allocated to receive
PINCER 
30 399 patients at risk
at baseline
(for all outcomes)
2 patients excluded from
outcome 3 analysis because
of data quality problems
0 practices lost to follow-up
0 patients lost to follow-up*
16 patients excluded from
outcome 3 analysis because
of data quality problems
0 practices lost to follow-up
0 patients lost to follow-up*
11 patients excluded from
outcome 3 analysis because
of data quality problems
36 practices analysed 
35 470 patients at risk
(for all outcomes)
36 practices analysed 
32 647 patients at risk
(for all outcomes)
0 practices lost to follow-up
0 patients lost to follow-up*
6 patients excluded from
outcome 3 analysis because
of data quality problems
0 practices lost to follow-up
0 patients lost to follow-up*
17 patients excluded from
outcome 3 analysis because
of data quality problems
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37 659 patients at risk
(for all outcomes)
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34 413 patients at risk
(for all outcomes)
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acceptability curve to express the probability that the cost 
per extra unit of outcome (error avoided in this study) 
gained from the trial was cost eﬀ ective as a function of 
the decision-maker’s ceiling cost-eﬀ ectiveness ratio (λ). 
We did a sensitivity analysis to establish incremental 
cost-eﬀ ectiveness ratios when the time horizon was 
12 months. A detailed description of the analysis is 
provided in the trial protocol.19 This study is registered, 
number ISRCTN21785299.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the manuscript. The corresponding author 
had full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
240 practices in Nottinghamshire, Staﬀ ordshire, and 
central and eastern Cheshire, England, were invited to 
participate, of which 72 (30%) were recruited between 
July 11, 2006, and Aug 8, 2007 (ﬁ gure 1). Participating 
and non-participating practices had much the same 
numbers of family doctors and socioeconomic proﬁ les, 
however, participating practices were larger, more likely 
to be training practices, and had slightly higher quality 
Patient characteristics Simple feedback PINCER Adjusted odds 
ratio (95% CI)*
ICC
Primary outcomes
1 History of peptic ulcer prescribed an NSAID without a PPI/history of peptic 
ulcer without a PPI
86/2014 (4%) 51/1852 (3%) 0·58 (0·38–0·89) 4·68×10⁷
2 Asthma prescribed a β blocker/asthma 658/22 224 (3%) 499/20 312 (2%) 0·73 (0·58–0·91) 3·50×10⁷
3 Aged ≥75 years receiving long-term ACE inhibitors or loop diuretics 
without urea and electrolyte monitoring in the previous 15 months/aged 
≥75 years receiving long-term ACE inhibitors or diuretics
436/5329 (8%) 255/4851 (5%) 0·51 (0·34–0·78) 0·14
Secondary outcomes
2a Asthma and not CHD prescribed a β blocker/asthma and not CHD 387/21 048 (2%) 299/19 286 (2%) 0·81 (0·63–1·04) 4·94×10⁶
4 History of venous or arterial thrombosis prescribed combined oral 
contraceptives/history of venous or arterial thrombosis (women)
8/2783 (<1%) 3/2490 (<1%) 0·39 (0·07–2·15) 0·05
5a Methotrexate for ≥3 months without full blood count in past 3 months/
methotrexate for ≥3 months
162/518 (31%) 122/494 (25%) 0·80 (0·45–1·43) 0·15
5b Methotrexate for ≥3 months without a liver function test in past 
3 months/ methotrexate for ≥3 months
154/518 (30%) 121/494 (24%) 0·79 (0·43–1·45) 0·17
6 Warfarin for ≥3 months without an INR in past 3 months/warfarin for 
≥3 months
78/1618 (5%) 52/1720 (3%) 0·53 (0·29–0·95) 1·11×10⁶
7 Lithium for ≥3 months without a lithium concentration measurement in 
past 3 months/lithium for ≥3 months
84/211 (40%) 67/190 (35%) 0·53 (0·24–1·19) 0·24
8 Amiodarone for ≥6 months without a thyroid function test in the past 
6 months/amiodarone for ≥6 months
106/235 (45%) 81/242 (33%) 0·57 (0·36–0·92) 4·86×10⁷
9 Methotrexate without instructions to take weekly/patients prescribed 
methotrexate
16/310 (5%) 2/268 (1%) 0·72 (0·06–9·25) 5·20×10⁷
10 Amiodarone for ≥1 month at a dose of >200 mg per day/amiodarone for 
≥1 month
1/228 (<1%) 1/228 (<1%) 0·96 (0·06–15·55)† 2·1×10⁵
11 At least one prescription problem/at risk of at least one prescription problem 752/26 329 (3%) 553/24 073 (2%) 0·71 (0·59–0·86) 9·16×10⁷
12 At least one monitoring problem/at risk of at least one monitoring problem 868/7409 (12%) 584/6963 (8%) 0·56 (0·44–0·70) 0·04
Data are numerator/denominator (%), unless otherwise stated. Numbers of patients does not equal the sum of the denominators in each group because only those with 
baseline and follow-up data are included. PINCER=pharmacist-led information technology intervention. NSAID=non-steroidal anti-inﬂ ammatory drug. ACE=angiotensin 
converting enzyme. PPI=proton-pump inhibitor. CHD=coronary heart disease. INR=international normalised ratio. ICC=intraclass correlation coeﬃ  cients. *Adjusted for 
randomisation stratum, baseline prevalence of errors, deprivation, and training status unless otherwise stated. †Adjustment for other variables not calculable.
Table 3: Prevalence of prescription and monitoring problems at 6 months’ follow-up by allocation group
At baseline At 6 months At 12 months
Simple feedback PINCER Simple feedback PINCER Simple feedback PINCER
Outcome 1 55 (7–129) 51 (9–124) 56 (10–130) 51 (11–120) 56 (12–136) 51 (12–115)
Outcome 2 573 (93–1215) 525 (94–1356) 617 (106–1307) 564 (104–1438) 653 (111–1381) 593 (118–1499)
Outcome 3 131 (22–379) 121 (18–287) 148 (26–462) 135 (21–331) 161 (30–492) 146 (22–365)
Data are mean (range). PINCER=pharmacist-led information technology intervention.
Table 2: Mean number of patients per practice for each primary outcome measure
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and outcomes framework scores, than did non-
participating practices (webappendix). Table 2 shows the 
number of patients per practice with each primary 
outcome measure. The main reason practices gave for 
not taking part was that they were too busy. In the simple 
feedback group, three practices had a small list size, 14 a 
medium list size, and 19 a large list size. In the PINCER 
group, four practices had a small list size, 13 a medium 
list size, and 19 a large list size. Table 1 shows participant 
charactersistics and the webappendix shows practice 
characteristics at baseline for the two treatment groups.
Table 3 shows results for the primary and secondary 
outcome measures at 6 months. For the primary 
outcomes, participants in the PINCER group were 
signiﬁ cantly less likely to have been prescribed a NSAID 
without a PPI if they had a history of peptic ulcer, 
a β blocker if they had asthma, or an ACE inhibitor or 
diuretic without having had urea and electrolytes 
measured in the preceding 15 months (table 3). Treatment 
group and practice size or deprivation did not interact 
signiﬁ cantly (data not shown). The intraclass correlation 
coeﬃ  cients estimated from the models for the NSAID 
and β-blocker outcomes were smaller than those used in 
the sample size calculations, whereas those for the ACE 
inhibitor or diuretic outcome were larger.
We identiﬁ ed issues with three of our secondary 
outcome measures.19 As a result, we excluded seven 
practices from the analysis of outcome 6, and 11 practices 
from outcomes 9 and 10. Participants in the PINCER 
group were signiﬁ cantly less likely to have a prescription 
error or monitoring problem (table 3). Participants were 
also signiﬁ cantly less likely to have been prescribed 
warfarin without monitoring in the previous 3 months 
or prescribed amiodarone without a thyroid function 
test in the past 6 months (table 3). Treatment groups 
did not diﬀ er for other secondary outcome measures. 
We identiﬁ ed no signiﬁ cant interactions between 
treatment group and practice size or deprivation (data 
not shown).
At 12-months’ follow-up participants in the PINCER 
group were still signiﬁ cantly less likely to have been 
prescribed a β blocker if they had a history of asthma, 
or prescribed an ACE inhibitor or diuretic without 
assess ment of urea and electrolytes in the past 
Patient characteristics Simple feedback PINCER Adjusted odds 
ratio* (95% CI)
ICC
Primary outcomes
1 History of peptic ulcer prescribed an NSAID without a PPI/history of peptic 
ulcer without a PPI
78/2035 (4%) 61/1852 (3%) 0·91 (0·59–1·39) 6·54×10⁷
2 Asthma prescribed a β blocker/asthma 692/23 520 (3%) 545/21 359 (3%) 0·78 (0·63–0·97) 0·008
3 Aged ≥75 years receiving long-term ACE inhibitors or loop diuretics without 
urea and electrolyte monitoring in the previous 15 months/aged ≥75 years 
receiving long-term ACE inhibitors or diuretics
452/5813 (8%) 306/5242 (6%) 0·63 (0·41–0·95) 0·13
Secondary outcome measures
2a Asthma and not CHD prescribed a β blocker/asthma and not CHD 414/22 294 (2%) 326/20 283 (2%) 0·79 (0·62–1·02) 0·009
4 History of venous or arterial thrombosis prescribed combined oral 
contraceptives/history of venous or arterial thrombosis (women)
15/2987 (1%) 4/2640 (<1%) 0·57 (0·05–6·17) 0·24
5a Methotrexate for ≥3 months without full blood count in past 3 months/
methotrexate for ≥3 months
194/552 (35%) 130/531 (24%) 0·51 (0·27–0·99) 0·22
5b Methotrexate for ≥3 months without a liver function test in past 3 months/
methotrexate for ≥3 months
186/552 (34%) 134/531 (25%) 0·50 (0·28–0·91)† 0·16
6 Warfarin for ≥3 months without an INR in past 3 months/warfarin for 
≥3 months
69/1752 (4%) 76/1877 (4%) 0·98 (0·52–1·85) 0·10
7 Lithium for ≥3 months without a lithium concentration measurement in 
past 3 months/lithium for ≥3 months
88/213 (41%) 56/176 (32%) 0·50 (0·29–0·85) 0·02
8 Amiodarone for ≥6 months without a thyroid function test in the past 6 
months/amiodarone for ≥6 months
92/247 (37%) 80/233 (34%) 0·77 (0·41–1·43) 0·11
9 Methotrexate without instructions to take weekly/patients prescribed 
methotrexate
13/309 (4%) 0/271 (0%) Not calculable ··
10 Amiodarone for ≥1 month at a dose of >200 mg per day/amiodarone for 
≥1 month
1/231 (<1%) 1/232 (<1%) 0·95 (0·06–15·45)‡ 1·07×10⁵
11 At least one prescription problem/at risk of at least one prescription problem 785/27 808 (3%) 610/25 246 (2%) 0·78 (0·64–0·94) 0·01
12 At least one monitoring problem/at risk of at least one monitoring problem 901/8011 (11%) 652/7449 (9%) 0·64 (0·51–0·82)† 0·05
Data are numerator/denominator (%), unless otherwise stated. Number of patients does not equal the sum of the denominators in each group, because only those with 
baseline and follow-up data are included. PINCER=pharmacist-led information technology intervention. NSAID=non-steroidal anti-inﬂ ammatory drug. ACE=angiotensin 
converting enzyme. PPI=proton-pump inhibitor. CHD=coronary heart disease. INR=international normalised ratio. ICC=intraclass correlation coeﬃ  cients. *Adjusted for 
randomisation stratum, baseline prevalence of errors, deprivation, and training status unless otherwise stated. †Includes interaction between treatment group and covariate 
dichotomised at the median value (≤median vs >median). ‡Adjustment for other variables not calculable.
Table 4: Prevalence of prescription and monitoring problems at 12 months’ follow-up by allocation group
For the quality and outcomes 
framework see http://www.qof.
ic.nhs.uk
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15 months (table 4). However, prescription of a non-
selective NSAID without a PPI for patients with a 
history of peptic ulcer was no longer signiﬁ cant (table 4). 
The intraclass correlation coeﬃ  cients estimated from 
the models for the NSAID outcome were smaller than 
those used in the sample size calculations, and those 
for the β blocker and ACE inhibitors or diuretic out-
comes were larger.
Participants in the PINCER group were overall still 
signiﬁ cantly less likely to have a prescription or 
monitoring problem at 12 months (table 4), and were 
signiﬁ cantly less likely to have been prescribed metho-
trexate without a full blood count or liver function test in 
the past 3 months (table 4). Patients were also signiﬁ cantly 
less likely to have been prescribed lithium without 
measurement of lithium concentration in the past 
3 months (table 4). Treatment groups did not diﬀ er 
for other secondary outcome measures (table 4). We 
identiﬁ ed no signiﬁ cant interactions between treatment 
group and practice or practice deprivation (data not 
shown). The models for primary outcomes, and all 
except three models for secondary outcomes, were 
robust to the exclusion of practices with standardised 
empirical Bayes estimates of random eﬀ ects above or 
below two standard deviations (data not shown). No 
adverse events were reported.
Three reports were run in each practice (at baseline, 
6 months, and 12 months), at a cost of £92∙84 (£1=US$1·56) 
per practice at 6 months follow-up, and £139∙26 per 
practice at 12 months follow-up. In total, generation of 
reports cost £3342∙24 for 36 simple feedback and 
36 PINCER intervention practices at 6 months and 
£5013∙36 for the same number of practices at 12 months. 
This was the only cost in the simple feedback group. The 
PINCER group also generated training costs of 
£9933∙26, preparation costs of £102∙89, facilitated 
meeting costs of £6976∙81, monthly meeting costs of 
£1996∙30, practice meeting costs of £794∙52, and error 
management costs of £14 641∙20. The cost components 
Simple feedback PINCER intervention Group comparison
Mean cost per practice (median, range)
Report generation
6 months £92·84 (NA) £92·84 (NA) ··
12 months £139·26 (NA) £139·26 (NA) ··
Pharmacist training £0 £275·92 (267·76, 79·54 to 591·23) ··
Quarterly facilitated strategic meetings £0 £195·23 (189·45, 56·28 to 418·33) ··
Monthly operational meetings £0 £56·88 (55·20, 16·40 to 121·88) ··
Practice feedback £0 £22·07 (21·42, 6·36 to 47·29) ··
Management of errors £0 £406·70 (320·93, 57·04 to 1318·68) ··
Total
6 months £92·84 (NA) £1049·67 (967·86, 329·22 to 2086·78) ··
12 months £139·26 (NA) £1096·09 (1014·28, 375·64 to 2133·20) ··
Mean incremental cost (SD, 95% CI)
6 months ·· ·· £871·88 (54·04, 765·96 to 977·79)
12 months ·· ·· £870·63 (53·60, 858·42 to 1 068·52)
Mean incremental errors (SD, 95% CI)
6 months ·· ·· –12·90 (0·26, –13·42 to –12·39)
12 months ·· ·· –12·71 (0·29, –13·27 to –12·14)
Mean ICER (2·5th–97·5th percentile; cost per error avoided)
6 months ·· ·· £65·60 (58·2 to 73·0)
12 months ·· ·· £66·53 (66·8 to 81·5)
£1=US$1·56. NA=not applicable. ICER=incremental cost-eﬀ ectiveness ratio. PINCER=pharmacist-led information technology-based intervention.
Table 5: Costs, outcomes, and incremental economic analyses associated with PINCER intervention and simple feedback
Figure 2: Cost-eﬀ ectiveness acceptability curves at 6 and 12 months
PINCER=pharmacist-led information technology-based intervention.
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were added to give the total mean cost per practice in 
each group of the trial (webappendix).
Adjusted costs were estimated by generalised linear 
modelling with the assumption of a γ distribution 
(webappendix). Only baseline list size was signiﬁ cant 
(webappendix).
Table 5 summarises the costs and outcomes used 
in the incremental cost-eﬀ ectiveness analysis and 
ﬁ g ure 2 shows the cost-eﬀ ectiveness acceptability curves 
at 6 months and 12 months. This analysis sug gests that 
PINCER had a 95% probability of being cost eﬀ ective if 
the decision-maker’s ceiling willingness to pay reached 
£75 per error avoided (at 6 months) or £85 per error 
avoided (at 12 months). Because the error reduction is 
sustained at 12 months, this analysis suggests that the 
intervention could be delivered yearly, rather than every 
6 months, and still retain equivalent cost-eﬀ ectiveness.
Discussion
This trial shows that the PINCER intervention is more 
eﬀ ective than simple feedback for reduction of the 
numbers of patients at risk from hazardous prescribing 
and inadequate blood-test monitoring of medicines in 
general practice. In view of the high risk of serious 
iatrogenic harm associated with errors, reductions of 
the magnitude noted in this trial are likely to be 
clinically important.
The main strengths of this study include the 
pragmatic design, the large numbers of practices 
enrolled, and the range of clinically relevant outcomes 
tested. We avoided bias in allocation of practices by use 
of an independent centralised web-based randomisation 
service, and the sequence of treatment allocations was 
masked until all data analyses had been completed. 
Also, none of the practices were lost to follow-up. 
Because the data were extracted electronically from 
general practice computer systems, and those who 
cleaned the data were masked to treatment allocation, 
no risk of bias existed. Analyses were undertaken 
independently by two statisticians, masked to treatment 
allocation, both producing similar ﬁ ndings. When 
minor diﬀ erences were identiﬁ ed, the reasons for these 
were explored and discrepancies resolved. Although 
some of the intraclass correlation coeﬃ  cients estimated 
from our models were larger than those used in our 
sample size calculations, this diﬀ erence did not result 
in insuﬃ  cient power because signiﬁ cant eﬀ ects were 
shown for those outcomes.
The simple feedback we used as a control is superior to 
routine models of care used in the UK, therefore the true 
eﬀ ect size of PINCER in comparison to standard care 
might have been underestimated. We have also sought to 
assess the sustained eﬀ ect of PINCER at 12 months after 
the intervention.
We have undertaken an embedded longitudinal 
qualitative assessment, which shows that general practice 
staﬀ  are receptive to the PINCER intervention and that 
the introduction of the intervention was a valuable 
educational experience for them (Creswell K, unpub-
lished). Our parallel cohort study in 438 practices 
throughout England conﬁ rms that the trial’s ﬁ ndings can 
be generalised widely (Shiekh A, unpublished).
However, our trial does have some limitations. Practices 
that agreed to participate and those that did not diﬀ ered 
slightly (webappendix). The characteristics of the groups 
were much the same, but the intervention practices were 
slightly more deprived and likely to be training practices 
than were control practices (webappendix). We therefore 
adjusted for these two factors in our analysis. Moreover, 
results of our parallel national cohort study showed that 
the frequency of these errors was much the same in a 
large sample of non-intervention practices, suggesting 
that the practices enrolled in this trial are likely to be 
representative of practices nationwide. Although data 
extraction for our prespeciﬁ ed primary outcome measures 
worked successfully in all general practices recruited for 
the study, we encountered some diﬃ  culties with three of 
the secondary outcome measures. Finally, our sample size 
calculations were made on the basis of assessment of 
outcomes at the main 6 month assessment point; therefore 
the study might have been underpowered to assess 
outcomes at 12 months.
We deliberately focused on potential medication errors 
rather than adverse events and therefore we cannot be 
certain that the pharmacist-led intervention will reduce 
harm to patients. Nevertheless, a strong argument can be 
made for focus on the measurement of errors rather than 
on adverse events for assessment of the quality of clinical 
practice, as the former relate most closely to actions that 
are within the control of health-care professionals.28
We are developing an economic model incorporating 
the clinical and economic eﬀ ects of changes in error rates 
to allow calculation of costs per quality-adjusted life-
years. Little equivalent work about this topic has been 
done. An exploratory economic modelling study29 
estimated that a pharmacy-based intervention to reduce 
medication errors would have a probability of being cost 
eﬀ ective with a quality-adjusted life-year value of 
£10 000 of more than 60%. This ﬁ nding suggests that 
pharmacist-led interventions to reduce error rates have 
the potential to be cost eﬀ ective according to currently 
used cost-eﬀ ectiveness thresholds. The webappendix 
contains further discussion of the economic analysis.
Since the start of our trial, important studies have 
questioned the eﬀ ectiveness of isolated pharmacist-
centred interventions in general practice. For example, 
the HOMER trial17 aimed to assess whether home-based 
medication review by pharmacists in older people would 
aﬀ ect hospital readmission rates. The researchers 
reported an increase in hospital admissions and no 
improvement in quality of life or death rate. The RESPECT 
trial16 showed no beneﬁ t of involvement of community 
pharmacists in the moderation of drug management 
(pharmaceutical care) in older people in general practice. 
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Findings are awaited from a trial in the USA assessing 
the eﬀ ectiveness of a pharmacist intervention for reduc-
tion of medication errors after hospital discharge for 
high-risk patients with cardio vascular disease.30
In view of the conﬂ icting evidence for the eﬀ ectiveness 
of pharmacist-led interventions in primary care, the 
eﬀ ectiveness of PINCER should be considered (panel 2). 
First, we used an educational outreach approach, which 
is a moderately powerful intervention for changing 
profes sional behaviour.14 Pharmacists who took part in 
the trial received training on the use of these techniques 
and the evidence base for the outcome measures used in 
the trial. Second, we focused on speciﬁ c examples of 
hazardous prescription or inadequacies in medication 
monitoring, which might have increased our ability 
to detect change compared with more generalised 
measures. Third, the pharmacists established working 
relations with the practices, which granted them access 
to patient records for contextual information and the 
mandate to provide practical support to make changes to 
patients’ medications and organise blood tests. Fourth, 
the intervention was multifaceted, used the potential 
oﬀ ered by information technology, and aimed to simul-
taneously tackle diﬀ erent barriers to change; such 
interventions are known to be more eﬀ ective than are 
simpler interventions.34
Because of the pressing need to reduce errors in 
health care,4–6 PINCER oﬀ ers an eﬀ ective method for 
reducing a range of medication errors in general 
practice. An essential prerequisite is the use of 
electronic health records, which eﬀ ectively reduces 
errors.7–9 The intervention that we have developed will 
be suitable for implementation in the increasing 
number of countries where clinical records are now 
computerised and where the roles of pharmacists to 
monitor proactively for clinically important medication 
errors can be extended.
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